CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines

Pancreatic cancer is one of the most aggressive diseases with a very poor outcome. Olaparib, a PARP inhibitor, as maintenance therapy showed benefits in patients with metastatic pancreatic adenocarcinoma bearing germline BRCA1/2 mutations. However, germline BRCA mutation has been described in only 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Witz, Andréa, Dardare, Julie, Francois, Aurélie, Husson, Marie, Rouyer, Marie, Demange, Jessica, Merlin, Jean-Louis, Gilson, Pauline, Harlé, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618219/
https://www.ncbi.nlm.nih.gov/pubmed/37907567
http://dx.doi.org/10.1038/s41598-023-45964-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618219/
https://www.ncbi.nlm.nih.gov/pubmed/37907567
http://dx.doi.org/10.1038/s41598-023-45964-w

Ejemplares similares